Filing Flows › Protalix BioTherapeutics (PLX) › Q2 2026 › vs Q1 2026
Protalix BioTherapeutics (PLX) Q2 2026 vs Q1 2026 (quarter over quarter)
Protalix BioTherapeutics's revenue fell $13.9M (-41%) from $33.8M in Q1 2026 to $19.9M in Q2 2026. The biggest changes: LICENSE AND R&D SERVICES −$26.3M (-100%); GOODS +$12.4M (+167%). Operating margin 23.5% against 62.7% (-39.2 pts).
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 23.5% | 62.7% | -39.2 pts |
| Net margin | 19.0% | 54.3% | -35.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| GOODS | $19.8M | $7.4M | $12.4M | +167% |
| LICENSE AND R&D SERVICES | $68K | $26.3M | −$26.3M | -100% |
| Revenue | $19.9M | $33.8M | −$13.9M | -41% |
| Other income, net | $188K | −$5K | $193K | — |
| Operating profit | $4.7M | $21.1M | −$16.5M | -78% |
| Costs & expenses | $15.2M | $12.6M | $2.6M | +21% |
| Pre-tax earnings | $4.9M | $21.1M | −$16.3M | -77% |
| Cost of revenue | $7.8M | $4.1M | $3.6M | +88% |
| Research & development | $4.4M | $5.4M | −$1.1M | -20% |
| SG&A | $3.1M | $3.1M | $60K | +2% |
| Net earnings | $3.8M | $18.3M | −$14.5M | -79% |
| Income tax | $1.1M | $2.8M | −$1.7M | -62% |
| Operating cash sources | $15.0M | −$2.8M | $17.8M | — |
| Depreciation | $406K | $404K | $2K | +0.5% |
| Share-based compensation | $398K | $532K | −$134K | -25% |
| Cash used in operations | $10.4M | −$22.0M | $32.4M | — |
| Working capital & other | $15.0M | −$2.8M | $17.8M | — |
Questions
How much did Protalix BioTherapeutics's revenue grow quarter over quarter in Q2 2026?
Protalix BioTherapeutics's revenue fell $13.9M (-41%) from $33.8M in Q1 2026 to $19.9M in Q2 2026.
What drove Protalix BioTherapeutics's revenue change in Q2 2026?
LICENSE AND R&D SERVICES −$26.3M (-100%); GOODS +$12.4M (+167%).